All-cause mortality and risk of death relative to demographic, clinical, and treatment-related factors among 1080 five-year survivors of pediatric non-Hodgkin lymphoma (NHL): Childhood Cancer Survivor Study, North America
| . | Total . | Deaths from NHL, n = 21 . | Deaths from other causes, n = 66 . | ||
|---|---|---|---|---|---|
| O . | RR (95% CI) . | O . | RR (95% CI) . | ||
| Sex | |||||
| Male | 760 | 18 | 1.0 | 44 | 1.0 |
| Female | 320 | 3 | 0.3 (0.01, 1.3) | 22 | 3.4 (1.9, 5.9) |
| Age at NHL diagnosis, y | |||||
| 0-4 | 184 | 3 | 1.0 | 7 | 1.0 |
| 5-9 | 325 | 3 | 0.7 (0.2, 2.2) | 19 | 1.0 (0.4, 3.1) |
| 10-14 | 346 | 7 | 0.6 (0.1, 2.2) | 20 | 1.0 (0.4, 3.2) |
| 15-21 | 225 | 8 | 2.0 (0.4, 6.9) | 20 | 0.9 (0.4, 2.9) |
| Year of NHL diagnosis | |||||
| 1970-1973 | 122 | 8 | 1.2 (0.4, 4.8) | 20 | 1.9 (0.8, 4.7) |
| 1974-1977 | 211 | 1 | 0.2 (0.01, 1.2) | 16 | 1.4 (0.6, 3.3) |
| 1978-1981 | 310 | 7 | 1.1 (0.3, 4.2) | 18 | 1.1 (0.5, 2.8) |
| 1982-1986 | 437 | 5 | 1.0 | 12 | 1.0 |
| P trend=.098 | |||||
| NHL histopathology or cell type | |||||
| Burkitt/Burkitt-like | 245 | 1 | 1.0 | 7 | 1.0 |
| Lymphoblastic | 243 | 5 | 3.8 (0.6, 74.0) | 17 | 2.3 (0.8, 7.1) |
| Diffuse large cell | 217 | 7 | 5.2 (0.9, 96.9) | 15 | 2.0 (0.8, 6.2) |
| Others, specified | 142 | 3 | 2.4 (0.2, 51.0) | 12 | 2.0 (0.6, 6.7) |
| Unspecified | 233 | 5 | 4.0 (0.6, 76.4) | 15 | 1.9 (0.7, 6.0) |
| Treatment exposures* | |||||
| Any RT | 633 | 17 | 2.5 (0.7, 16.1) | 45 | 1.7 (0.8, 3.9) |
| Cardiac exposure to RT | 122 | 6 | 1.8 (0.6, 4.8) | 15 | 1.9 (1.0, 3.6) |
| Any CT | 870 | 16 | 1.4 (0.4, 8.9) | 50 | 1.1 (0.5, 3.2) |
| COMP | 668 | 13 | Unable | 34 | 1.1 (0.4, 3.2) |
| Ara-C | 411 | 12 | 5.0 (1.9, 14.8) | 25 | 1.4 (0.7, 2.4) |
| Doxorubicin | 293 | 10 | 4.0 (1.6, 10.6) | 21 | 1.8 (1.0, 3.1) |
| Epipodophyllotoxins | 83 | 6 | 9.4 (3.1, 25.6) | 7 | 1.5 (0.5, 3.6) |
| Bleomycin | 56 | 8 | 14.5 (5.4, 38.2) | 7 | 2.4 (1.0, 5.0) |
| Platinum compounds | 14 | 5 | 85.6 (26.1, 242) | 2 | 4.7 (0.8, 16.0) |
| Bone marrow transplantation | 26 | 3 | 10.0 (2.2, 31.8) | 3 | 2.7 (0.7, 7.5) |
| . | Total . | Deaths from NHL, n = 21 . | Deaths from other causes, n = 66 . | ||
|---|---|---|---|---|---|
| O . | RR (95% CI) . | O . | RR (95% CI) . | ||
| Sex | |||||
| Male | 760 | 18 | 1.0 | 44 | 1.0 |
| Female | 320 | 3 | 0.3 (0.01, 1.3) | 22 | 3.4 (1.9, 5.9) |
| Age at NHL diagnosis, y | |||||
| 0-4 | 184 | 3 | 1.0 | 7 | 1.0 |
| 5-9 | 325 | 3 | 0.7 (0.2, 2.2) | 19 | 1.0 (0.4, 3.1) |
| 10-14 | 346 | 7 | 0.6 (0.1, 2.2) | 20 | 1.0 (0.4, 3.2) |
| 15-21 | 225 | 8 | 2.0 (0.4, 6.9) | 20 | 0.9 (0.4, 2.9) |
| Year of NHL diagnosis | |||||
| 1970-1973 | 122 | 8 | 1.2 (0.4, 4.8) | 20 | 1.9 (0.8, 4.7) |
| 1974-1977 | 211 | 1 | 0.2 (0.01, 1.2) | 16 | 1.4 (0.6, 3.3) |
| 1978-1981 | 310 | 7 | 1.1 (0.3, 4.2) | 18 | 1.1 (0.5, 2.8) |
| 1982-1986 | 437 | 5 | 1.0 | 12 | 1.0 |
| P trend=.098 | |||||
| NHL histopathology or cell type | |||||
| Burkitt/Burkitt-like | 245 | 1 | 1.0 | 7 | 1.0 |
| Lymphoblastic | 243 | 5 | 3.8 (0.6, 74.0) | 17 | 2.3 (0.8, 7.1) |
| Diffuse large cell | 217 | 7 | 5.2 (0.9, 96.9) | 15 | 2.0 (0.8, 6.2) |
| Others, specified | 142 | 3 | 2.4 (0.2, 51.0) | 12 | 2.0 (0.6, 6.7) |
| Unspecified | 233 | 5 | 4.0 (0.6, 76.4) | 15 | 1.9 (0.7, 6.0) |
| Treatment exposures* | |||||
| Any RT | 633 | 17 | 2.5 (0.7, 16.1) | 45 | 1.7 (0.8, 3.9) |
| Cardiac exposure to RT | 122 | 6 | 1.8 (0.6, 4.8) | 15 | 1.9 (1.0, 3.6) |
| Any CT | 870 | 16 | 1.4 (0.4, 8.9) | 50 | 1.1 (0.5, 3.2) |
| COMP | 668 | 13 | Unable | 34 | 1.1 (0.4, 3.2) |
| Ara-C | 411 | 12 | 5.0 (1.9, 14.8) | 25 | 1.4 (0.7, 2.4) |
| Doxorubicin | 293 | 10 | 4.0 (1.6, 10.6) | 21 | 1.8 (1.0, 3.1) |
| Epipodophyllotoxins | 83 | 6 | 9.4 (3.1, 25.6) | 7 | 1.5 (0.5, 3.6) |
| Bleomycin | 56 | 8 | 14.5 (5.4, 38.2) | 7 | 2.4 (1.0, 5.0) |
| Platinum compounds | 14 | 5 | 85.6 (26.1, 242) | 2 | 4.7 (0.8, 16.0) |
| Bone marrow transplantation | 26 | 3 | 10.0 (2.2, 31.8) | 3 | 2.7 (0.7, 7.5) |
Results are based on demographic data presented for 1080 subjects who completed the baseline questionnaire, excluding two with unknown date of death.
O indicates observed; RR, rate ratio (based on Poisson regression); analyses are adjusted for sex and RT exposure.
Treatment data were available for 921 subjects, including 73 of 87 deaths. RT, radiation therapy; CT, chemotherapy; COMP, cyclophosphamide, vincristine, methotrexate, and prednisone. The referent group for each treatment exposure consists of subjects who did not receive that treatment. Treatment results are adjusted for NHL and histopathology. CT and BMT results are additionally adjusted for RT.